Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pradefovir - Ligand Pharmaceuticals

Next Previous
Drug Profile

Pradefovir - Ligand Pharmaceuticals

Alternative Names: Hepavir B; ICN-2001-3; MB-06866; MB-6866; Pradefovir mesylate; Remofovir; Remofovir mesylate; UNII-GZE85Q9Q61

Latest Information Update: 12 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Metabasis Therapeutics
  • Developer Ligand Pharmaceuticals; Valeant Pharmaceuticals International; Xian Xintong Pharmaceutical Research
  • Class Adenine nucleotides; Antivirals; Organophosphorus compounds; Purines; Small molecules
  • Mechanism of Action DNA-directed DNA polymerase inhibitors; Hepatitis B virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Hepatitis B

Most Recent Events

  • 28 Oct 2024 Registered for Hepatitis B in China (PO)
  • 10 Nov 2023 Efficacy and adverse events data from a phase III trial in Hepatitis B presented at the 74th Annual Meeting of the American Association for the Study of Liver Disease (AASLD-2023)
  • 09 Aug 2023 Preregistration for Hepatitis B in China (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top